Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Müllerian duct maintenance at the cranial region is promoted by Gata2

ABSTRACT: The paradigm of sexual differentiation holds that female embryos retain Müllerian ducts (the precursor of female reproductive tract organs) by default in the absence of anti-Müllerian hormone (AMH). Whether Müllerian duct maintenance requires active signaling has remained unclear. Here, we show that deletion of mesenchymal Gata2 induces selective regression of the cranial Müllerian duct (future oviduct). This regression did not result from ectopic AMH signaling but from loss of region-specific NRG1 signaling. In contrast, the caudal Müllerian duct (future uterus) was retained but displayed disrupted epithelial differentiation when Gata2 was deleted in either mesenchymal or epithelial compartments. Our findings reveal a region-specific, GATA2-dependent program that actively maintains the cranial Müllerian duct, reshaping our understanding of female reproductive tract development.

ORGANISM(S): Mus musculus

PROVIDER: GSE324404 | GEO | 2026/03/16

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Osterix functions downstream of anti-Müllerian hormone signaling to regulate Müllerian duct regression

Project description:The goal of this study was to identify potential AMH-induced genes and regulatory networks controlling regression by RNA-Seq transcriptome analysis of differences in Müllerian Duct mesenchyme between males (AMH signaling on) and females (AMH signaling off) in purified fetal Müllerian Duct mesenchymal cells. This analysis found 82 genes up-regulated in males during MD regression and identified Osterix (Osx)/Sp7, a key transcriptional regulator of osteoblast differentiation and bone formation, as a novel downstream effector of AMH signaling during MD regression.

2018-07-16 | GSE116157 | GEO

Transcriptome and chromatin accessiblity analysis of Gli1+ and Amhr2+ mesenchymes in the fetal murine reproductive tracts

Project description:Precursors for the male and female reproductive tracts (also known as the Wolffian duct and the Müllerian duct) co-exist in a mammalian embryo before sexual differentiation. The Wolffian duct and Müllerian duct are surrounded by their own mesenchymes in the mesonephros, which can be distinguished by their specific expression of Gli1 and Amhr2, respectively. In the XX embryo, during sexual differentiation, the Wolffian duct degenerates. In this study, by tracking the fate of the Gli1+ Wolffian duct mesenchyme in the tamoxifen inducible genetic lineage tracing model Gli1-CreER; Rosa-Tomato, we demonstrate that the Wolffian duct mesenchyme does not regress along with the Wolffian duct epithelium in the XX embryo. Instead, the Wolffian duct mesenchyme is repurposed and becomes a unique mesenchymal population in the female reproductive tract. Profiling the transcriptomes and chromatin accessibilities of the Gli1+ Wolffian duct mesenchyme in XX and XY during sexual differentiation (E14.5 and E16.5) shows signaling pathways and transcriptional factors that potentially involves the female and male fate differentiation of the Gli1+ Wolffian duct mesenchyme. Comparing the transcriptomes between the Gli1+ Wolffian duct mesenchyme and the Amhr2+ Müllerian duct mesenchyme from the neonatal uterus reveals similarities and differences between the two mesenchymal populations in the female reproductive tract. Ex vivo ablation of the Wolffian duct mesenchyme stunted the growth of the fetal female reproductive tract. In summary, our discovery of the contribution of the Wolffian duct mesenchyme to the female reproductive tract provides new insights into our understanding of sexual differentiation of reproductive tracts.

2022-10-05 | GSE179876 | GEO

A Wnt7a-Hoxa13 pathway for Müllerian duct fusion at the body midline for uterine morphogenesis

Project description:During embryonic development, the Müllerian ducts and adjacent mesenchyme differentiate into the tissues of the oviducts, uterus, cervix, and upper vagina. Variations in the fusion process can alter typical uterine morphology, correlating with an increased incidence of infertility, high-risk pregnancy, and miscarriage. We show that Wnt7a is required for Müllerian duct fusion at the body midline to generate the bipartite uterus of the mouse. Wnt7a null female mice form Müllerian ducts, but the ducts do not fuse at the midline resulting in a duplex reproductive tract (two separate uterine horns, two cervices, and two vaginas). Spatial transcriptome analysis of Wnt7a null and control fusion regions identified a downregulation of Hoxa13 in Wnt7a-null mesenchyme compared to wild type. Reduction in Hoxa13/HOXA13 is associated with didelphic uterine formation. These studies identify a Wnt7a-Hoxa13 genetic pathway that regulates uterine morphology.

2026-02-07 | GSE318449 | GEO

Evaluation of the roles of Lats1 and Lats2 in the development of the Müllerian ducts

Project description:Development of the female tract results from the carefull coordination of numerous signaling pathways. Here, we evaluated the role of hippo pathway in the development of the female reproductive tract. We used microarray to compare the gene expression changes observed in the Müllerian ducts of E17.5 mice embryos between control group and experimental (mutant) group bearing a conditional deletion of both (conjoint) Lats1 and Lats2 using the Amhr2cre strain.

2019-10-10 | GSE135855 | GEO

Inhibitory Actions of Anti-Müllerian Hormone (AMH) on Ovarian Primordial Follicle Assembly

Project description:The current study was designed to investigate the actions of Anti-Müllerian Hormone (AMH) on primordial follicle assembly. Ovarian primordial follicles develop from the breakdown of oocyte nests during fetal development for the human and immediately after birth in rodents. AMH was found to inhibit primordial follicle assembly, decrease the initial primordial follicle pool size and promote the persistence of small oocyte nests in a rat ovarian organ culture. The AMH expression was found to be primarily in the stromal tissue of the ovaries at this period of development, suggesting a stromal-epithelial cell interaction for primordial follicle assembly. AMH was found to promote alterations in the ovarian transcriptome during primordial follicle assembly with over 200 genes with altered expression. A gene network was identified suggesting a potential central role for the Fgf2/Nudt6 antisense transcript in the follicle assembly process. A number of signal transduction pathways are regulated by AMH actions on the ovarian transcriptome, in particular the transforming growth factor – beta (TGFß) signaling process. AMH is the first hormone/protein shown to have an inhibitory action on primordial follicle assembly. Due to the critical role of the primordial follicle pool size for female reproduction, elucidation of the factors, such as AMH, that regulate the assembly process will provide insights into potential therapeutics to manipulate the pool size and female reproduction. We used microarrays to determine genes expressed differentially between control and AMH (Anti-Müllerian Hormone) treated P0 ovary

2011-03-04 | GSE25629 | GEO

Expression data from anti-müllerian hormone treated preantral/small antral mouse ovary follicles

2015-05-01 | E-GEOD-56737 | biostudies-arrayexpress

Anti-Müllerian Hormone Ameliorates Uterine DNA Damage Response and Prevents Pregnancy Complications in Doxorubicin-Treated Mice

Project description:Anti-Müllerian hormone (AMH) has emerged as a potential fertoprotective agent, demonstrating its strongest protective effects against Doxorubicin (DOX)-induced ovarian toxicity. While chemotherapy’s gonadotoxic impact on ovaries has been extensively studied, its effects on the uterus remain poorly understood. In this study, we investigated DOX-induced uterine damage and assessed the protective role of AMH co-treatment. DOX triggered DNA double-strand breaks in the uterine myometrium, activating Cdkn1a and other Tp53 pathway genes, and was linked to increased dystocia in pregnant mice. AMH co-treatment counteracted these effects by reducing γ-H2AX-positive DNA damage foci, suppressing Tp53 pathway activation, and improving pregnancy outcomes. These findings establish AMH as a promising therapeutic agent for preserving uterine integrity during chemotherapy, opening new avenues for fertility preservation and improved reproductive health in cancer patients.

2025-08-31 | GSE290107 | GEO

Anti-Müllerian Hormone Reduces Uterine DNA Damage and Pregnancy Complications in Doxorubicin-Treated Mice [RNA-seq]

2025-08-31 | GSE289996 | GEO

Expression data from anti-müllerian hormone treated preantral/small antral mouse ovary follicles

2015-05-01 | GSE56737 | GEO

Gene expression data from anti-müllerian hormone (AMH) treated mouse ovary follicles

Project description:Anti-müllerian hormone (AMH) has an inhibitory effect on ovarian follicle development. However, the mechanism by which AMH regulates folliculogenesis remains to be elucidated. In this study we aimed to investigate the changes in transcriptome of preantral to small antral mice follicles after culturing with AMH and thereby identify candidate genes to be involved. This study is a repetition of a previous study (GEO accession .no.: GSE56737) at the concentration of 50 ng/mL. The overall design are almost similar to GSE56737 except that it was performed in quadruplicate. Preantral to small antral follicles were collected from dissected ovaries from six to eight weeks old female C57BL/6Tac mice. Twelve hour as well as 24 hour experiments were performed in one fixed concentration of AMH and an untreated control. The experiments were performed in quadroplicate. In total 16 samples: 2 x conc. (control and 50 ng/ml AMH), 2 x time points, 4 x experiments (quadroplicate). Samples are pairwise comparable within each experiment, that is, sample 1-2 or 3-4 or 5-6 or 7-8 or 9-10 or 11-12 or 13-14 or 15-16. Data are also comparable groupwise; (1,5,9,13) vs (2,6,10,14) or (3,7,11,15) vs (4,8,12,16).

2015-05-01 | E-GEOD-63907 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data